Q4 2014 13F Holders as of 31 Dec 2014
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
6.52M
-
Shares change
-
-60.5K
-
Total reported value, excl. options
-
$75.9M
-
Value change
-
-$6.54M
-
Number of buys
-
31
-
Number of sells
-
-20
-
Price
-
$11.64
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2014
62 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2014.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.52M shares
of 236M outstanding shares and own 2.76% of the company stock.
Largest 10 shareholders include Novo A/S (1.52M shares), EAGLE ASSET MANAGEMENT INC (1.22M shares), HealthCor Management, L.P. (845K shares), FMR LLC (724K shares), BlackRock Fund Advisors (457K shares), VANGUARD GROUP INC (231K shares), BALYASNY ASSET MANAGEMENT LLC (229K shares), MORGAN STANLEY (124K shares), Cormorant Asset Management, LLC (118K shares), and MILLENNIUM MANAGEMENT LLC (115K shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.